Lebrikizumab Delivers Clinically Meaningful and Continuous Improvement in Itch-Free Days in Atopic Dermatitis Through One Year

Main Article Content

Gil Yosipovitch
University of Miami Miller School of Medicine, Miami, USA

Claudia Zeidler
University Hospital Münster, Münster, Germany

Christian J. Apfelbacher
Otto von Guericke University, Magdeburg, Germany and Nanyang Technological University, Singapore

Vivian Laquer
First OC Dermatology Research, Fountain Valley, USA

Brian S. Kim
Icahn School of Medicine at Mount Sinai, New York, USA

Marta Casillas
Eli Lilly and Company, Indianapolis, USA

Evangeline Pierce
Eli Lilly and Company, Indianapolis, USA

Sherry Chen
Tigermed, Hangzhou, China

Meihua Qiao
Tigermed, Hangzhou, China

Helena Agell
Almirall, S.A., Barcelona, Spain

James Del Rosso
JDR Dermatology Research and Thomas Dermatology, Las Vegas, USA

Keywords

Lebrikizumab, atopic dermatitis, itch

References

1. Silverberg JI, et al. N Engl J Med. 2023;388:1080-1091.

2. Okragly AJ, et al. Dermatol Ther (Heidelb). 2023;13:1535-1547.

3. Moyle M, et al. Exp Dermatol. 2019;28:756-768.

4. Blauvelt A, et al. Br J Dermatol. 2023;188:740-748.

5. Yosipovitch G, et al. Br J Dermatol. 2022;186:135-185.

6. Yosipovitch G, et al. Br J Dermatol. 2019;181:761-769.

Article Sidebar

PDF
Published
Nov 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.273

Article Details

How to Cite
[1]
Yosipovitch, G. , Zeidler, C. , Apfelbacher, C.J. , Laquer, V. , Kim, B.S. , Casillas, M. , Pierce, E. , Chen, S. , Qiao, M. , Agell, H. and Del Rosso, J. 2023. Lebrikizumab Delivers Clinically Meaningful and Continuous Improvement in Itch-Free Days in Atopic Dermatitis Through One Year. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s273. DOI:https://doi.org/10.25251/skin.7.supp.273.
Issue
Vol. 7 No. 6 (2023): November 2023 Issue
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

1 2 3 4 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

<< < 4 5 6 7 8 9